Trial Profile

A Phase Ib/II, Single-arm, Multi-center Clinical Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Toripalimab (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Shanghai Junshi Biosciences

Most Recent Events

07 Jun 2022 Preliminary results of the phase Ib portion presented at the 58th Annual Meeting of the American Society of Clinical Oncology
06 Jun 2022 According to Junshi Biosciences media release, results presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
06 Jun 2022 Preliminary results published in the Shanghai Junshi Biosciences Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com